Patents by Inventor Shaoqiang Huang
Shaoqiang Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11725000Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: GrantFiled: May 28, 2021Date of Patent: August 15, 2023Assignee: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
-
Patent number: 11666577Abstract: The invention provides compounds that inhibit human MLKL, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: GrantFiled: August 26, 2019Date of Patent: June 6, 2023Assignee: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Bo Yan, Lei Liu, Huayi Wang, Jianguang Han, Zhi Huang, Weiye Cao
-
Patent number: 11453674Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.Type: GrantFiled: January 18, 2019Date of Patent: September 27, 2022Assignee: EVOPOINT BIOSCIENCES CO., LTD.Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu, Linhai Qu, Jinlian Zhu, Xiao Liu
-
Patent number: 11180475Abstract: Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.Type: GrantFiled: November 8, 2018Date of Patent: November 23, 2021Assignee: SinoMab BioScience LimitedInventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu
-
Publication number: 20210308141Abstract: The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2.Type: ApplicationFiled: July 26, 2019Publication date: October 7, 2021Inventors: Wei Peng, Jun Xian, Yonghan Hu, Yuchuan Wu, Xi Chen, Shaoqiang Huang, Xiao Liu, Xin Li, Bin Huang, Dongdong Wu
-
Publication number: 20210309647Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: ApplicationFiled: May 28, 2021Publication date: October 7, 2021Applicant: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
-
Patent number: 11078202Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.Type: GrantFiled: August 20, 2020Date of Patent: August 3, 2021Assignee: SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.Inventors: Yuchuan Wu, Shaoqiang Huang, Xi Chen, Yonghan Hu, Xiao Liu
-
Patent number: 11034680Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: GrantFiled: January 15, 2019Date of Patent: June 15, 2021Assignee: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
-
Publication number: 20210046057Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.Type: ApplicationFiled: January 24, 2019Publication date: February 18, 2021Inventors: Yuchuan WU, Shaoqiang HUANG, Xi CHEN, Yonghan HU, Xiao LIU
-
Publication number: 20210032260Abstract: Provided are a ?-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the ?-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.Type: ApplicationFiled: August 20, 2020Publication date: February 4, 2021Inventors: Yuchuan WU, Shaoqiang HUANG, Xi CHEN, Yonghan HU, Xiao LIU
-
Publication number: 20200361902Abstract: Disclosed is a new crystal form of a 5-aminopyrazole carboxamide compound as shown in Formula (I). Also disclosed are a preparation method for said crystal form of said compound, a pharmaceutical composition of said crystal form of said compound, and uses thereof.Type: ApplicationFiled: November 8, 2018Publication date: November 19, 2020Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu
-
Publication number: 20200347070Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.Type: ApplicationFiled: January 18, 2019Publication date: November 5, 2020Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu, Linhai Qu, Jinlian Zhu, Xiao Liu
-
Publication number: 20190381052Abstract: The invention provides compounds that inhibit human MLKL, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: ApplicationFiled: August 26, 2019Publication date: December 19, 2019Applicant: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Bo Yan, Lei Liu, Huayi Wang, Jianguang Han, Zhi Huang, Weiye Cao
-
Publication number: 20190152960Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.Type: ApplicationFiled: January 15, 2019Publication date: May 23, 2019Applicant: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han